EUCTR2007-007258-75-IT进行中（未招募）不适用
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) - 20060198
Amgen Inc.0 个研究点目标入组 240 人开始时间: 2008年9月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of MDS using the WHO classification
- •Per MDS IPSS, low or intermediate-1 risk MDS
- •The mean of the two platelet counts taken within 4 weeks prior to randomization must be:
- •o ≤ 20 x 109/L, with no individual count >30 x 109/L, with or without a history of bleeding, OR
- •o ≤ 50 x 109/L, with no individual count >60 x 109/L with a history of bleeding.
- •A standard of care platelet count taken prior to Informed Consent may be used as 1 of the 2 counts taken within 4 weeks prior to randomization
- •Subjects must be ≥18 and ≤ 90 years of age at the time of informed consent. Subjects between 85 and 90 years of age must have been diagnosed with MDS ≤ 5 years from study start.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Adequate liver function, as evidenced by a serum bilirubin ≤ 2 times the laboratory normal range and unconjugated bilirubin ≥ 90% of total bilirubin (except for patients with a confirmed diagnosis of Gilbert?s Disease), ALT ≤ 3 times the laboratory normal range, and AST ≤3 times the laboratory normal range
- •A serum creatinine concentration ≤ 2 mg/dl (≤176.8 μmol/L)
- •Bone marrow biopsy and aspirate with cytogenetics within 3 months of starting first dose of investigational product
- •Written Informed Consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Have ever received any disease-modifying treatment for MDS
- •Previously diagnosed with intermediate-2 or high risk MDS using the IPSS
- •Prior history of leukemia, aplastic anemia, or other non-MDS related bone marrow stem cell disorder
- •Prior history of hematopoietic stem cell transplantation
- •Persistent peripheral blood monocytosis (≥ 3 months with an absolute monocyte count >1,000/μL)
- •Prior malignancy (other than in situ cervical cancer, non-melanoma skin cancer, or in situ carcinoma) unless treated with curative intent and without evidence of disease for ≥ 3 years before randomization
- •Active or uncontrolled infections
- •Unstable angina, congestive heart failure (NYHA > class II), uncontrolled hypertension (diastolic >100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
- •History of arterial thrombosis (eg, stroke or transient ischemic attack) within the past year
- •History of venous thrombosis that currently requires anti-coagulation therapy
- •Received IL-11 within 4 weeks of the first dose of investigational product
- •Have previously received any thrombopoietic growth factor
- •Receipt of G-CSF, peg-G-CSF, or GM-CSF within 4 weeks of the first dose of investigational product
- •Planned receipt of peg-G-CSF or GM-CSF after the first dose of investigational product
- •Pregnant or breast feeding
- •Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator. Amgen recommends double barrier contraception is used for all applicable patients enrolled on this study. A double barrier method is defined as two methods of contraception, for example 2 actual barrier methods, or one actual barrier method and one hormonal method.
- •Known hypersensitivity to any recombinant E coli-derived product
- •Any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
- •Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s)
研究者
相似试验
尚未招募
3 期
Effectiveness of Bacillus Coagulans in improving appetite among patients admitted in hospitalCTRI/2018/11/016404Hindu Mission Hospital
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate HypertensioMen and women, 35-70 years old with mild to moderate Hypertension as classified by the British Hypertension Society (BHS) Guidelines - BHS-IV based on the following crietia of sitting blood pressure measured by spygomanography for patienst without diabetes or renal dysfunction:Grade 1 (mild): Systolic BP 140-159 mmHG and Diastolic BP of 90-99 mmHgGrade 2 (moderate): Systolic BP 160-179 mmHg and Diastolic BP 100-109 mmHgMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10042957Term: Systolic hypertensionMedDRA version: 9.1Level: PTClassification code 10012758Term: Diastolic hypertensionEUCTR2008-001001-41-GBProtherics Medicines Development Ltd, a BTG plc company
已完成
不适用
Effectiveness and safety of a herbal composition to improve Aging Male SymptomsCTRI/2019/02/017506aila Neutraceuticals Pvt Ltd
招募中
3 期
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Aerosolized JH509 in Hospitalized Adult Patients with Mild to Moderate COVID 19COVID-19 infections diseaseJPRN-jRCT2051200159Shoji Hashimoto385
已完成
不适用
A study of Cordyceps Capsules as an Add-On Therapy in patients with moderate COVID 19 InfectioCTRI/2020/09/028131Ambrosia Food Farm Co